[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344139-105":59,"doc-detail-344139-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-organoids-as-reliable-disease-models-to-drive-clinical-development-of-novel-therapies-meeting-report","Cancer Organoids as Reliable Disease Models to Drive Clinical Development of Novel Therapies - Meeting Report","","Meeting report on the 6th IRE Translational Oncology Workshop (September 23–24, 2024) held at the IRCCS Regina Elena Cancer Institute in Rome. The program centers on patient-derived 3D tumor organoid models and addresses the challenge of modeling a dynamic tumor ecosystem with spatial and temporal evolution. The report highlights how organoids, explants, and bioprinted systems support precision oncology by capturing microenvironment interactions, enabling study of treatment resistance and metastatic dynamics, and accelerating the translation from preclinical research to personalized therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-organoids-as-reliable-disease-models-to-drive-clinical-development-of-novel-therapies-meeting-report/344139/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-organoids-as-reliable-disease-models-to-drive-clinical-development-of-novel-therapies-meeting-report/344139.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What workshop and where did it take place?","Question",{"text":112,"@type":113},"The 6th IRE Translational Oncology Workshop was held on September 23–24, 2024 at the IRCCS Regina Elena Cancer Institute in Rome.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are patient-derived 3D organoid models important in precision oncology?",{"text":117,"@type":113},"They capture tumor heterogeneity and key cell-to-cell and cell-to-microenvironment interactions, addressing unmet needs in clinical decision-making and drug response prediction.",{"name":119,"@type":110,"acceptedAnswer":120},"How do organoids help accelerate translation into clinical therapies?",{"text":121,"@type":113},"They enable modeling of treatment resistance and metastatic dynamics and support screening approaches that help move findings from preclinical research toward more personalized and effective treatments.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344139,1790322922,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Blandino et al. J Exp Clin Cancer Res (2024) 43:334 [https://doi.org/10.1186/s13046-024-03258-7](https://doi.org/10.1186/s13046-024-03258-7)  \nJournal of Experimental & Clinical Cancer Research  \n MEETING REPORT Open Access  \nCancer Organoids as reliable disease models   to drive clinical development of novel therapies  \nGiovanni Blandino1*, Ronit Satchi‑Fainaro2, Ingeborg Tinhofer3, Giovanni Tonon4, Sarah C. Heilshorn5, Yong‑Jun Kwon6, Ana Pestana3, Carlotta Frascolla 1, Luca Pompili 1, Aurora Puce7, Sara Iachettini 1, Annalisa Tocci8, Sofia Karkampouna9, Marianna Kruithof‑de Julio9, PieraTocci10, Nicla Porciello8, Klizia Maccaroni7, Daniela Rutigliano1, Xiling Shen11,12 and Gennaro Ciliberto13  \nAbstract  \nOn September 23–24 (2024) the 6th Workshop IRE on Translational Oncology, titled“Cancer Organoids as Reliable Dis‑ ease Models to Drive Clinical Development of Novel Therapies,” took place at the IRCCS Regina Elena Cancer Institute in Rome. This prominent international conference focused on tumor organoids, bringing together leading experts from around the world.  \nA central challenge in precision oncology is modeling the dynamic tumor ecosystem, which encompasses numer‑ ous elements that evolve spatially and temporally. Patient‑derived 3D culture models, including organoids, explants, and engineered or bioprinted systems, have recently emerged as sophisticated tools capable of capturing the com‑ plexity and diversity of cancer cells interacting within their microenvironments. These models address critical unmet needs in precision medicine, particularly in aiding clinical decision‑making. The rapid development of these human tissue avatars has enabled advanced modeling of cellular alterations in disease states and the screening of com‑ pounds to uncover novel therapeutic pathways.  \nThroughout the event, distinguished speakers shared their expertise and research findings, illustrating how orga‑ noids are transforming our understanding of treatment resistance, metastatic dynamics, and the interaction between tumors and the surrounding microenvironment.  \nThis conference served as a pivotal opportunity to strengthen international collaborations and spark innovative trans‑ lational approaches. Its goal was to accelerate the shift from preclinical research to clinical application, paving the way for increasingly personalized and effective cancer therapies.  \nKeywords Organoid, Precision medicine, Patient‑derived 3D culture model, Targeted therapy, Preclinical models, Cancer spheroid  \n*Correspondence: Giovanni Blandino [giovanni.blandino@ifo.it](giovanni.blandino@ifo.it)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativecom](http://creativecom)‑ [mons.org/publicdomain/zero/1.0/](mons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless other","cbCaimPprYramYKr","https://ap.wps.com/l/cbCaimPprYramYKr","pdf",2995018,16,"English","# Abstract\n# Drug screening in tumor organoids\n# 3D-bioprinted cancer models for target discovery, drug development, and personalized therapy","[{\"question\":\"What workshop and where did it take place?\",\"answer\":\"The 6th IRE Translational Oncology Workshop was held on September 23–24, 2024 at the IRCCS Regina Elena Cancer Institute in Rome.\"},{\"question\":\"Why are patient-derived 3D organoid models important in precision oncology?\",\"answer\":\"They capture tumor heterogeneity and key cell-to-cell and cell-to-microenvironment interactions, addressing unmet needs in clinical decision-making and drug response prediction.\"},{\"question\":\"How do organoids help accelerate translation into clinical therapies?\",\"answer\":\"They enable modeling of treatment resistance and metastatic dynamics and support screening approaches that help move findings from preclinical research toward more personalized and effective treatments.\"}]","Cancer Organoids as Reliable Disease Models to Drive Clinical Development of Novel Therapies - Meeting Report | PDF",1790053101,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f5187ab22033ca934c90fb1c0507eb3.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d90d37d61f2c4177701ee87f2fefcd71.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b145abc62fa714f4c151253b1f369fcf.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96ade66786ec0c95ba06014200e98bb0.webp",980,1301]